Novartis unit Sandoz reported that its biosimilar version of adalimumab had safety and efficacy profiles similar to those of AbbVie's Humira, and its rituximab matched the safety and efficacy of Roche and Biogen's Rituxan.
Sandoz reports clinical trial data on 2 biosimilars
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.